About this Journal Submit a Manuscript Table of Contents
Journal of Skin Cancer
Volume 2011 (2011), Article ID 274382, 19 pages
http://dx.doi.org/10.1155/2011/274382
Research Article

Adjuvant Therapy: Melanoma

1Division of General Internal Medicine, University of Pittsburgh Medical Center, 200 Lothrop Street, Pittsburgh, PA 15213, USA
2Division of Hematology-Oncology, University of Pittsburgh Medical Center, 5150 Centre Avenue, Pittsburgh, PA 15232, USA

Received 12 August 2011; Accepted 1 October 2011

Academic Editor: Mohammed Kashani-Sabet

Copyright © 2011 Diwakar Davar et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. R. Middleton, J. J. Grob, N. Aaronson et al., “Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma,” Journal of Clinical Oncology, vol. 18, no. 1, pp. 158–166, 2000. View at Scopus
  2. P. M. Patel, S. Suciu, L. Mortier, et al., “Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032),” European Journal of Cancer, vol. 47, no. 10, pp. 1476–1483, 2011.
  3. F. S. Hodi, S. J. O'Day, D. F. McDermott et al., “Improved survival with ipilimumab in patients with metastatic melanoma,” The New England Journal of Medicine, vol. 363, no. 8, pp. 711–723, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. C. Robert, L. Thomas, I. Bondarenko, et al., “Ipilimumab plus dacarbazine for previously untreated metastatic melanoma,” The New England Journal of Medicine, vol. 364, no. 26, pp. 2517–2526, 2011.
  5. P. B. Chapman, A. Hauschild, C. Robert, et al., “BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation,” The New England Journal of Medicine, vol. 364, no. 26, pp. 2507–2516, 2011.
  6. M. B. Atkins, J. Hsu, S. Lee et al., “Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group,” Journal of Clinical Oncology, vol. 26, no. 35, pp. 5748–5754, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. C. Garbe and T. K. Eigentler, “Diagnosis and treatment of cutaneous melanoma: state of the art 2006,” Melanoma Research, vol. 17, no. 2, pp. 117–127, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. A. A. Tarhini and J. M. Kirkwood, “Clinical and immunologic basis of interferon therapy in melanoma,” Annals of the New York Academy of Sciences, vol. 1182, pp. 47–57, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. M. B. Lens and M. Dawes, “Interferon alfa therapy for malignant melanoma: a systematic review of randomized controlled trials,” Journal of Clinical Oncology, vol. 20, no. 7, pp. 1818–1825, 2002. View at Publisher · View at Google Scholar · View at Scopus
  10. K. Wheatley, N. Ives, B. Hancock, M. Gore, A. Eggermont, and S. Suciu, “Does adjuvant interferon-α for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials,” Cancer Treatment Reviews, vol. 29, no. 4, pp. 241–252, 2003. View at Publisher · View at Google Scholar · View at Scopus
  11. K. Wheatley, B. Hancock, M. Gore, et al., “Interferon-{alpha} as adjuvant therapy for melanoma: an individual patient data meta-analysis of randomised trials,” Journal of Clinical Oncology, vol. 25, no. 18, p. 8526, 2007.
  12. S. Mocellin, S. Pasquali, C. R. Rossi, and D. Nitti, “Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis,” Journal of the National Cancer Institute, vol. 102, no. 7, pp. 493–501, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. C. M. Balch, A. C. Buzaid, S. J. Soong et al., “Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma,” Journal of Clinical Oncology, vol. 19, no. 16, pp. 3635–3648, 2001. View at Scopus
  14. L. Zhuang, R. A. Scolyer, R. Murali et al., “Lactate dehydrogenase 5 expression in melanoma increases with disease progression and is associated with expression of Bcl-XL and Mcl-1, but not Bcl-2 proteins,” Modern Pathology, vol. 23, no. 1, pp. 45–53, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. S. Nagata, N. Mantei, and C. Weissmann, “The structure of one of the eight or more distinct chromosomal genes for human interferon-α,” Nature, vol. 287, no. 5781, pp. 401–408, 1980. View at Scopus
  16. S. J. Moschos, H. D. Edington, S. R. Land et al., “Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses,” Journal of Clinical Oncology, vol. 24, no. 19, pp. 3164–3171, 2006. View at Publisher · View at Google Scholar · View at Scopus
  17. W. Wang, H. D. Edington, D. M. Jukic, U. N. M. Rao, S. R. Land, and J. M. Kirkwood, “Impact of IFNα2b upon pSTAT3 and the MEK/ERK MAPK pathway in Melanoma,” Cancer Immunology, Immunotherapy, vol. 57, no. 9, pp. 1315–1321, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Kortylewski, M. Kujawski, A. Herrmann et al., “Toll-like receptor 9 activation of signal transducer and activator of transcription 3 constrains its agonist-based immunotherapy,” Cancer Research, vol. 69, no. 6, pp. 2497–2505, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. M. Kortylewski, R. Jove, and H. Yu, “Targeting STAT3 affects melanoma on multiple fronts,” Cancer and Metastasis Reviews, vol. 24, no. 2, pp. 315–327, 2005. View at Publisher · View at Google Scholar · View at Scopus
  20. E. T. Creagan, R. J. Dalton, D. L. Ahmann et al., “Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma,” Journal of Clinical Oncology, vol. 13, no. 11, pp. 2776–2783, 1995. View at Scopus
  21. J. M. Kirkwood, M. H. Strawderman, M. S. Ernstoff, T. J. Smith, E. C. Borden, and R. H. Blum, “Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group trial EST 1684,” Journal of Clinical Oncology, vol. 14, no. 1, pp. 7–17, 1996. View at Scopus
  22. J. M. Kirkwood, J. G. Ibrahim, V. K. Sondak et al., “High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190,” Journal of Clinical Oncology, vol. 18, no. 12, pp. 2444–2458, 2000. View at Scopus
  23. J. M. Kirkwood, J. G. Ibrahim, J. A. Sosman et al., “High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801,” Journal of Clinical Oncology, vol. 19, no. 9, pp. 2370–2380, 2001. View at Scopus
  24. P. O. Livingston, G. Y. C. Wong, S. Adluri et al., “Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside,” Journal of Clinical Oncology, vol. 12, no. 5, pp. 1036–1044, 1994. View at Scopus
  25. J. M. Kirkwood, J. Ibrahim, D. H. Lawson et al., “High-dose interferon alfa-2b does not diminish antibody response to GM2 vaccination in patients with resected melanoma: results of the multicenter eastern cooperative oncology group phase II trial E2696,” Journal of Clinical Oncology, vol. 19, no. 5, pp. 1430–1436, 2001. View at Scopus
  26. J. M. Kirkwood, J. Manola, J. Ibrahim, V. Sondak, M. S. Ernstoff, and U. Rao, “A pooled analysis of Eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma,” Clinical Cancer Research, vol. 10, no. 5, pp. 1670–1677, 2004. View at Publisher · View at Google Scholar · View at Scopus
  27. D. Pectasides, U. Dafni, D. Bafaloukos et al., “Randomized phase III study of 1 month versus 1 year of adjuvant high-dose interferon alfa-2b in patients with resected high-risk melanoma,” Journal of Clinical Oncology, vol. 27, no. 6, pp. 939–944, 2009. View at Publisher · View at Google Scholar · View at Scopus
  28. S. S. Agarwala, S. J. Lee, L. E. Flaherty, et al., “Randomized phase III trial of high-dose interferon alfa-2b (HDI) for 4 weeks induction only in patients with intermediate- and high-risk melanoma (Intergroup trial E 1697),” Journal of Clinical Oncology, vol. 29, p. 8505, 2011.
  29. C. Chao, S. L. Wong, M. I. Ross, et al., “Patterns of early recurrence after sentinel lymph node biopsy for melanoma,” The American Journal of Surgery, vol. 184, no. 6, pp. 520–225, 2002.
  30. V. Chiarion-Sileni, M. Guida, A. Romanini, et al., “Intensified high-dose intravenous interferon alpha 2b (IFNa2b) for adjuvant treatment of stage III melanoma: a randomized phase III Italian Melanoma Intergroup (IMI) trial [ISRCTN75125874],” Journal of Clinical Oncology, vol. 29, p. 8506, 2011.
  31. A. M. Eggermont, S. Suciu, R. MacKie et al., “Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial,” The Lancet, vol. 366, no. 9492, pp. 1189–1196, 2005. View at Publisher · View at Google Scholar · View at Scopus
  32. J. J. Grob, B. Dreno, P. de la Salmoniere, et al., “Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma,” The Lancet, vol. 351, no. 9120, pp. 1905–1910, 1998.
  33. K. Wheatley, N. Ives, and A. M. Eggermont, “Interferon-a as adjuvant therapy for melanoma: an individual patient data meta-analysis of the randomized trials,” in Proceedings of the American Society of Clinical Oncology 43rd Annual Meeting, vol. 25, p. 8526, Chicago, Ill, USA, June 2007.
  34. C. Garbe, P. Radny, R. Linse et al., “Adjuvant low-dose interferon α2a with or without dacarbazine compared with surgery alone: a prospective-randomized phase III DeCOG trial in melanoma patients with regional lymph node metastasis,” Annals of Oncology, vol. 19, no. 6, pp. 1195–1201, 2008. View at Publisher · View at Google Scholar · View at Scopus
  35. A. Hauschild, M. Weichenthal, K. Rass et al., “Efficacy of low-dose interferon α2a 18 versus 60 months of treatment in patients with primary melanoma of ≥ 1.5 mm tumor thickness: results of a randomized phase III DeCOG trial,” Journal of Clinical Oncology, vol. 28, no. 5, pp. 841–846, 2010. View at Publisher · View at Google Scholar · View at Scopus
  36. J. Hansson, S. Aamdal, L. Bastholt, et al., “Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trial,” The Lancet Oncology, vol. 12, no. 2, pp. 144–152, 2011.
  37. S. Zeuzem and F. Poordad, “Pegylated-interferon plus ribavirin therapy in the treatment of CHC: individualization of treatment duration according to on-treatment virologic response,” Current Medical Research and Opinion, vol. 26, no. 7, pp. 1733–1743, 2010. View at Publisher · View at Google Scholar · View at Scopus
  38. A. Potthoff, H. Wedemeyer, W. O. Boecher et al., “The HEP-NET B/C co-infection trial: a prospective multicenter study to investigate the efficacy of pegylated interferon-α2b and ribavirin in patients with HBV/HCV co-infection,” Journal of Hepatology, vol. 49, no. 5, pp. 688–694, 2008. View at Publisher · View at Google Scholar · View at Scopus
  39. E. Jenny Heathcote, “Antiviral therapy: chronic hepatitis C,” Journal of Viral Hepatitis, vol. 14, no. 1, pp. 82–88, 2007. View at Publisher · View at Google Scholar · View at Scopus
  40. A. M. Eggermont, S. Suciu, M. Santinami et al., “Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial,” The Lancet, vol. 372, no. 9633, pp. 117–126, 2008. View at Publisher · View at Google Scholar · View at Scopus
  41. J. J. Grob, T. Jouary, B. Dreno, et al., “Adjuvant therapy with pegylated interferon alfa-2b (36 months) versus low-dose interferon alfa-2b (18 months) in melanoma patients without macro-metastatic nodes: EADO trial,” Journal of Clinical Oncology, vol. 28, no. 15, p. LBA8506, 2010.
  42. U. R. Kleeberg, S. Suciu, E. B. Bröcker, et al., “Final results of the EORTC 18871/DKG 80-1 randomised phase III trial. rIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or regional lymph node metastasis,” European Journal of Cancer, vol. 40, no. 3, pp. 390–402, 2004.
  43. N. Cascinelli, R. Bufalino, A. Morabito, and R. MacKie, “Results of adjvant interferon study in WHO melanoma programme,” Lancet, vol. 343, no. 8902, pp. 913–914, 1994. View at Publisher · View at Google Scholar · View at Scopus
  44. B. W. Hancock, K. Wheatley, S. Harris et al., “Adjuvant interferon in high-risk melanoma: the AIM HIGH study—United Kingdom Coordinating Committee on cancer research randomized study of adjuvant low-dose extended-duration interferon alfa-2a in high-risk resected malignant melanoma,” Journal of Clinical Oncology, vol. 22, no. 1, pp. 53–61, 2004. View at Publisher · View at Google Scholar · View at Scopus
  45. D. A. Cameron, M. C. Cornbleet, R. M. Mackie, J. A. A. Hunter, M. Gore, and B. Hancock, “Adjuvant interferon alpha 2b in high risk melanoma—the scottish study,” The British Journal of Cancer, vol. 84, no. 9, pp. 1146–1149, 2001. View at Publisher · View at Google Scholar · View at Scopus
  46. H. Gogas, D. Bafaloukos, J. Ioannovich et al., “Tolerability of adjuvant high-dose interferon alfa-2b: 1 month versus 1 year—a Hellenic Cooperative Oncology Group study,” Anticancer Research, vol. 24, no. 3 B, pp. 1947–1952, 2004. View at Scopus
  47. R. J. Sullivan, A. Frankenthaler, W. Wang, et al., “A retrospective comparison of 12 weeks versus 52 weeks of adjuvant interferon for patients with stage IIB, IIC, and IIIA (IIB-IIIA) melanoma (Mel),” Journal of Clinical Oncology, vol. 28, p. e19013, 2010.
  48. S. G. Thacker, C. C. Berthier, D. Mattinzoli, M. P. Rastaldi, M. Kretzler, and M. J. Kaplan, “The detrimental effects of IFN-α on vasculogenesis in lupus are mediated by repression of IL-1 pathways: Potential role in atherogenesis and renal vascular rarefaction,” Journal of Immunology, vol. 185, no. 7, pp. 4457–4469, 2010. View at Publisher · View at Google Scholar · View at Scopus
  49. M. J. Kaplan, “Premature vascular damage in systemic lupus erythematosus,” Autoimmunity, vol. 42, no. 7, pp. 580–586, 2009. View at Publisher · View at Google Scholar · View at Scopus
  50. T. R. O'Brien, “Interferon-alfa, interferon-lambda and hepatitis C,” Nature Genetics, vol. 41, no. 10, pp. 1048–1050, 2009.
  51. J. J. Stuckert, A. A. Tarhini, S. Lee, C. Sander, and J. M. Kirkwood, “Interferon alfa-induced autoimmunity and serum S100 levels as predictive and prognostic biomarkers in high-risk melanoma in the ECOG-intergroup phase II trial E2696,” Journal of Clinical Oncology, vol. 25, no. 18S, p. 8506, 2007, ASCO Annual Meeting Proceedings Part I, 2007.
  52. A. A. Tarhini, J. Stuckert, S. Lee, C. Sander, and J. M. Kirkwood, “Prognostic significance of serum s100b protein in high-risk surgically resected melanoma patients participating in intergroup trial ECOG 1694,” Journal of Clinical Oncology, vol. 27, no. 1, pp. 38–44, 2009. View at Publisher · View at Google Scholar · View at Scopus
  53. H. Gogas, J. Ioannovich, U. Dafni et al., “Prognostic significance of autoimmunity during treatment of melanoma with interferon,” The New England Journal of Medicine, vol. 354, no. 7, pp. 709–718, 2006. View at Publisher · View at Google Scholar · View at Scopus
  54. J. T. Rubin, R. Day, R. Duquesnoy et al., “HLA-DQ1 is associated with clinical response and survival of patients with melanoma who are treated with interleukin-2,” Therapeutic Immunology, vol. 2, no. 1, pp. 1–6, 1995. View at Scopus
  55. F. M. Marincola, D. Venzon, D. White et al., “HLA association with response and toxicity in melanoma patients treated with interleukin 2-based immunotherapy,” Cancer Research, vol. 52, no. 23, pp. 6561–6566, 1992. View at Scopus
  56. H. Gogas, J. M. Kirkwood, C. S. Falk et al., “Correlation of molecular human leukocyte antigen typing and outcome in high-risk melanoma patients receiving adjuvant interferon,” Cancer, vol. 116, no. 18, pp. 4326–4333, 2010. View at Publisher · View at Google Scholar · View at Scopus
  57. S. Meyer, P. J. Wild, T. Vogt et al., “Methylthioadenosine phosphorylase represents a predictive marker for response to adjuvant interferon therapy in patients with malignant melanoma,” Experimental Dermatology, vol. 19, no. 8, pp. e251–e257, 2010. View at Publisher · View at Google Scholar · View at Scopus
  58. L. Y. Kong, A. Gelbard, J. Wei et al., “Inhibition of p-STAT3 enhances IFN-α efficacy against metastatic melanoma in a murine model,” Clinical Cancer Research, vol. 16, no. 9, pp. 2550–2561, 2010. View at Publisher · View at Google Scholar · View at Scopus
  59. L. Humpoliková-Adámková, J. Kovarík, L. Dusek, et al., “Interferon-alpha treatment may negatively influence disease progression in melanoma patients by hyperactivation of STAT3 protein,” European Journal of Cancer, vol. 45, no. 7, pp. 1315–1323, 2009. View at Publisher · View at Google Scholar · View at Scopus
  60. W. Wang, H. D. Edington, U. N. M. Rao et al., “Effects of high-dose IFNα.2b on regional lymph node metastases of human melanoma: modulation of STAT5, FOXP3, and IL-17,” Clinical Cancer Research, vol. 14, no. 24, pp. 8314–8320, 2008. View at Publisher · View at Google Scholar · View at Scopus
  61. H. Schmidt, J. S. Johansen, P. Sjoegren et al., “Serum YKL-40 predicts relapse-free and overall survival in patients with American Joint Committee on Cancer stage I and II melanoma,” Journal of Clinical Oncology, vol. 24, no. 5, pp. 798–804, 2006. View at Publisher · View at Google Scholar · View at Scopus
  62. H. Schmidt, J. S. Johansen, J. Gehl, P. F. Geertsen, K. Fode, and H. Von Der Maase, “Elevated serum level of YKL-40 is an independent prognostic factor for poor survival in patients with metastatic melanoma,” Cancer, vol. 106, no. 5, pp. 1130–1139, 2006. View at Publisher · View at Google Scholar · View at Scopus
  63. M. Krogh, I. J. Christensen, M. Bouwhuis, et al., “Prognostic value of serum YKL-40 in stage IIB-III melanoma patients receiving adjuvant interferon therapy,” Journal of Clinical Oncology, vol. 28, no. 15s, p. 8587, 2010.
  64. J. P. Garnier, S. Letellier, B. Cassinat et al., “Clinical value of combined determination of plasma l-DOPA/tyrosine ratio, S100B, MIA and LDH in melanoma,” European Journal of Cancer, vol. 43, no. 4, pp. 816–821, 2007. View at Publisher · View at Google Scholar · View at Scopus
  65. J. Stahlecker, A. Gauger, A. Bosserhoff, R. Büttner, J. Ring, and R. Hein, “MIA as a reliable tumor marker in the serum of patients with malignant melanoma,” Anticancer Research, vol. 20, no. 6 D, pp. 5041–5044, 2000. View at Scopus
  66. U. Keilholz and M. E. Gore, “Biochemotherapy for advanced melanoma,” Seminars in Oncology, vol. 29, no. 5, pp. 456–461, 2002. View at Publisher · View at Google Scholar · View at Scopus
  67. S. S. Agarwala, D. Neuberg, Y. Park, and J. M. Kirkwood, “Mature results of a phase III randomized trial of bacillus Calmette-Guerin (BCG) versus observation and BCG plus dacarbazine versus BCG in the adjuvant therapy of American Joint Committee on Cancer Stage I-III melanoma (E1673): a Trial of the Eastern Cooperative Oncology Group,” Cancer, vol. 100, no. 8, pp. 1692–1698, 2004. View at Publisher · View at Google Scholar · View at Scopus
  68. V. Vantomme, P. Boël, E. De Plaen, T. Boon, and P. van der Bruggen, “A new tumor-specific antigenic peptide encoded by MAGE-6 is presented to cytolytic T lymphocytes by HLA-Cw16,” Cancer Immunity, vol. 3, p. 17, 2003. View at Scopus
  69. V. Vantomme, C. Dantinne, N. Amrani et al., “Immunologic analysis of a phase I/II study of vaccination with MAGE-3 protein combined with the AS02B adjuvant in patients with MAGE-3-positive tumors,” Journal of Immunotherapy, vol. 27, no. 2, pp. 124–135, 2004. View at Scopus
  70. W. Kruit, S. Suciu, B. Dreno, et al., “Active immunization toward the MAGE-A3 antigen in patients with metastatic melanoma: four-year follow-up results from a randomized phase II study (EORTC16032-18031),” Journal of Clinical Oncology, vol. 29, p. 8535, 2011.
  71. P. Livingston, “Ganglioside vaccines with emphasis on GM2,” Seminars in Oncology, vol. 25, no. 6, pp. 636–645, 1998. View at Scopus
  72. F. Helling, S. Zhang, A. Shang et al., “G(M2)-KLH conjugate vaccine: increased immunogenicity in melanoma patients after administration with immunological adjuvant QS-21,” Cancer Research, vol. 55, no. 13, pp. 2783–2788, 1995. View at Scopus
  73. A. M. Eggermont, S. Suciu, P. Rutkowski, et al., “Randomized phase III trial comparing postoperative adjuvant ganglioside GM2-KLH/QS-21 vaccination versus observation in stage II (T3-T4N0M0) melanoma: final results of study EORTC 18961,” 8505, vol. 28, no. 15s, p. 8505, 2010.
  74. P. Hersey, A. S. Coates, W. H. McCarthy et al., “Adjuvant immunotherapy of patients with high-risk melanoma using vaccinia viral lysates of melanoma: results of a randomized trial,” Journal of Clinical Oncology, vol. 20, no. 20, pp. 4181–4190, 2002. View at Publisher · View at Google Scholar · View at Scopus
  75. M. S. Mitchell, J. Abrams, J. A. Thompson et al., “Randomized trial of an allogeneic melanoma lysate vaccine with low-dose interferon alfa-2b compared with high-dose interferon alfa-2b for resected stage III cutaneous melanoma,” Journal of Clinical Oncology, vol. 25, no. 15, pp. 2078–2085, 2007. View at Publisher · View at Google Scholar · View at Scopus
  76. D. L. Morton, E. C. Hsueh, R. Essner, et al., “Prolonged survival of patients receiving active immunotherapy with Canvaxin therapeutic polyvalent vaccine after completeresection of melanoma metastatic to regional lymph nodes,” Annals of Surgery, vol. 236, no. 4, pp. 438–449, 2002.
  77. D. L. Morton, N. Mozzillo, J. F. Thompson, et al., “An international, randomized, phase III trial of bacillus Calmette-Guerin (BCG) plus allogeneic melanoma vaccine (MCV) or placebo after complete resection of melanoma metastatic to regional or distant sites,” Journal of Clinical Oncology, vol. 25, no. 18S, p. 8508, 2007, ASCO Annual Meeting Proceedings Part I, 2007.
  78. M. A. Henderson, B. Burmeister, J. F. Thompson, et al., “Adjuvant radiotherapy and regional lymph node field control in melanoma patients after lymphadenectomy: Results of an intergroup randomized trial (ANZMTG 01.02/TROG 02.01),” Journal of Clinical Oncology, vol. 27, no. 18s, p. LBA9084, 2009.
  79. O. Hamid, S. D. Chasalow, Z. Tsuchihashi, et al., “Association of baseline and onstudy tumor biopsy markers with clinical activity in patients (pts) with advancedmelanoma treated with ipilimumab,” Journal of Clinical Oncology, vol. 27, no. 15s, p. 9008, 2009.
  80. A. A. Tarhini, H. Edington, L. H. Butterfield, et al., “Neoadjuvant ipilimumab in patients with stage IIIB/C melanoma: immunogenicity and biomarker analysis,” Journal of Clinical Oncology, vol. 29, p. 8536, 2011.
  81. J. S. Weber, B. Yu, M. Hall, et al., “Pharmacodynamic and predictive markers of ipilimumab on melanoma patients’ T-cells,” Journal of Clinical Oncology, vol. 29, p. 2503, 2011.
  82. M. S. Ernstoff, M. Reiss, C. A. Davis, S. A. Rudnick, and J. M. Kirkwood, “Intravenous (IV) recombinant alpha-2 interferon (IFNα-2) in metastatic melanoma (abstr C-222),” Proceedings American Society of Clinical Oncology, vol. 2, p. 57, 1983.
  83. E. T. Creagan, D. L. Ahmann, and S. J. Green, “Phase II study of recombinant leukocyte A interferon (rIFN-αA) in disseminated malignant melanoma,” Cancer, vol. 54, no. 12, pp. 2844–2849, 1984. View at Scopus
  84. E. T. Creagan, D. L. Ahmann, and S. J. Green, “Phase II study of recombinant leukocyte A interferon (IFN-rA) plus cimetidine in disseminated malignant melanoma,” Journal of Clinical Oncology, vol. 3, no. 7, pp. 977–981, 1985. View at Scopus
  85. E. T. Creagan, D. L. Ahmann, and S. J. Green, “Phase II study of low-dose recombinant leukocyte A interferon in disseminated malignant melanoma,” Journal of Clinical Oncology, vol. 2, no. 9, pp. 1002–1005, 1984. View at Scopus
  86. S. S. Legha, N. E. J. Papadopoulos, C. Plager et al., “Clinical evaluation of recombinant interferon alfa-2a (Roferon-A) in metastatic melanoma using two different schedules,” Journal of Clinical Oncology, vol. 5, no. 8, pp. 1240–1246, 1987. View at Scopus
  87. P. Hersey, E. Hasic, and M. MacDonald, “Effects of recombinant leukocyte interferon (rIFN-αA) on tumour growth and immune responses in patients with metastatic melanoma,” The British Journal of Cancer, vol. 51, no. 6, pp. 815–826, 1985. View at Scopus
  88. J. R. Neefe, S. S. Legha, A. Markowitz et al., “Phase II study of recombinant α-interferon in malignant melanoma,” The American Journal of Clinical Oncology, vol. 13, no. 6, pp. 472–476, 1990. View at Scopus
  89. T. Dorval, T. Palangie, and M. Jouve, “Clinical Phase II trial of recombinant DNA interferon (interferon alfa 2b) in patients with metastatic malignant melanoma,” Cancer, vol. 58, no. 2, pp. 215–218, 1986. View at Scopus
  90. A. Coates, M. Rallings, P. Hersey, and C. Swanson, “Phase-II study of recombinant α2-interferon in advanced malignant melanoma,” Journal of Interferon Research, vol. 6, no. 1, pp. 1–4, 1986. View at Scopus
  91. M. G. Bouwhuis, S. Suciu, A. Testori et al., “Phase III trial comparing adjuvant treatment with pegylated interferon Alfa-2b versus observation: prognostic significance of autoantibodies–EORTC 18991,” Journal of Clinical Oncology, vol. 28, no. 14, pp. 2460–2466, 2010. View at Publisher · View at Google Scholar · View at Scopus
  92. H. Pehamberger, H. P. Soyer, A. Steiner, et al., “Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group,” Journal of Clinical Oncology, vol. 16, no. 4, pp. 1425–1429, 1998.
  93. J. J. Grob, B. Dreno, P. de la Salmonière, et al., “Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma,” The Lancet, vol. 351, no. 9120, pp. 1905–1910, 1998.
  94. N. Cascinelli, F. Belli, R. M. MacKie, M. Santinami, R. Bufalino, and A. Morabito, “Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomised trial,” The Lancet, vol. 358, no. 9285, pp. 866–869, 2001. View at Publisher · View at Google Scholar · View at Scopus
  95. A. Hauschild, M. Weichenthal, K. Rass et al., “Efficacy of low-dose interferon α2a 18 versus 60 months of treatment in patients with primary melanoma of ≥ 1.5 mm tumor thickness: results of a randomized phase III DeCOG trial,” Journal of Clinical Oncology, vol. 28, no. 5, pp. 841–846, 2010. View at Publisher · View at Google Scholar · View at Scopus
  96. U. Veronesi, J. Adamus, and C. Aubert, “A randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma,” The New England Journal of Medicine, vol. 307, no. 15, pp. 913–916, 1982. View at Scopus
  97. F. J. Lejeune, E. Macher, U. Kleeberg et al., “An assessment of DTIC versus levamisole or placebo in the treatment of high risk stage I patients after surgical removal of a primary melanoma of the skin. A phase III adjuvant study. EORTC protocol 18761,” European Journal of Cancer and Clinical Oncology, vol. 24, no. 2, pp. S81–S90, 1988. View at Scopus
  98. R. I. Fisher, W. D. Terry, and R. J. Hodes, “Adjuvant immunotherapy or chemotherapy for malignant melanoma. Preliminary report of the National Cancer Institute randomized clinical trial,” Surgical Clinics of North America, vol. 61, no. 6, pp. 1267–1277, 1981. View at Scopus
  99. H. S. Koops, M. Vaglini, S. Suciu, et al., “Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: results of a multicenter randomized phase III trial. European Organization for Research and Treatment of Cancer Malignant Melanoma Cooperative Group Protocol 18832, the World Health Organization Melanoma Program Trial 15, and the North American Perfusion Group Southwest Oncology Group-8593,” Journal of Clinical Oncology, vol. 16, no. 9, pp. 2906–2912, 1998.
  100. M. Maio, et al., “Efficacy and safety of ipilimumab in patients with advanced melanoma who had progressed on one or more prior therapies: results from a single-arm, multicenter study,” in Proceedings of the 33rd European Society for Medical Oncology Congress, Poster no.776PD, Stockholm, Sweden, September 2008.
  101. C. Lebbe, et al., “Effect of dose on efficacy and safety in Ipilimumab-treated patients with advanced melanoma: results from a phase II, randomized, dose-ranging study,” in Proceedings of the 33rd European Society for Medical Oncology Congress, Oral presentation no. 769O, Stockholm, Sweden, September 2008.
  102. R. Ridolfi, et al., “Efficacy and safety of treatment naïve and previously treated patients with advanced melanoma receiving ipilimumab,” in Proceedings of the 33rd European Society for Medical Oncology Congress, Poster no. 778PD, Stockholm, Sweden, September 2008.
  103. J. D. Wolchok, L. Thomas, I. N. Bondarenko, et al., “Phase III randomized study of ipilimumab (IPI) plus dacarbazine (DTIC) vs DTIC alone as first line treatment in patients with unresectable stage III or IV melanoma,” Journal of Clinical Oncology, vol. 29, abstract LBA5, 2011.
  104. A. Ribas, K. B. Kim, L. M. Schuchter, et al., “BRIM-2: an open-label, multicenter phase II study of vemurafenib in previously treated patients with BRAF V600E mutation-positive metastatic melanoma,” Journal of Clinical Oncology, vol. 29, abstract 8509, 2011.